Related Experiment Video
Updated: May 5, 2026

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis
Published on: December 8, 2011
[Clinical efficacy and safety of megestrol acetate vaginal ring]
Jin-feng Qian1, Xin-yi Zhu, Yi-wen Shen
1Department of Family Planning, Affiliated Obstetrics & Gynecology Hospital, Fudan University, Shanghai 200011, China.
Objective:
To explore the efficacy and safety of megestrol acetate silicone vaginal ring.
Methods:
A total of 165 healthy child-bearing age women were recruited to examine the efficacy, safety and satisfaction rate of megestrol acetate silicone vaginal ring.
Results:
The cumulative pregnancy rate of megestrol acetate silicone vaginal ring was 3.93%. And its discontinuation rate was 2.54%, the incidence of adverse events 11.52% and the incidence of adverse effects 1.81% while the symptoms were all slight. The bleeding pattern was similar to that of normal menstruation. Compared with baseline, the elevated level of triglycerides and the reduced level of low-density lipoprotein (LDL) were significantly different while no significant difference existed in high-density lipoprotein (HDL), cholesterol and hemoglobin, etc. The satisfaction rate of megestrol acetate silicone vaginal ring was 94.6% and increased with time.
Conclusion:
Megestrol acetate silicone vaginal ring is an effective and safe option of contraceptives.
Related Concept Videos
Intrauterine Drug Delivery Systems
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

